Skip to content
Search

Latest Stories

Pharmacy First service to launch next year

Pharmacy First service to launch next year

The new Pharmacy First Common Ailments service will be launched in January 2024 

This Pharmacy First Common Ailments service will help patients seek treatment for seven common conditions directly from a pharmacy without the need for a GP appointment or prescription.


Launching on 31 January next year although it is subject to IT being ready, the service will cover ailments including “sinusitis, sore throat, earache, infected insect bites, impetigo, shingles, and uncomplicated urinary tract infections (UTIs)” in women.

People with symptoms of the above seven conditions will be supplied with a prescription-only treatment under a Patient Group Direction (PGD).

Patients seeking assistance at the pharmacy, whether walk-in or referred by NHS 111, GPs, or other sources, can receive consultations.

The new service includes self-referring patients plus referrals, and the Community Pharmacist Consultation Service (CPCS) will also be a part of it.

Pharmacy First - payments 

CPE's negotiations were also aimed at key improvements for the community pharmacy including aims to "incentivise sign-up for the new services, generate capacity, reduce risk for pharmacy owners and establish conditions for business growth."

They secured an upfront payment of £2,000 per pharmacy ahead of the Pharmacy First launch to support pharmacy owners in preparing and building capacity for the new service.

Moreover, pharmacy owners gaining access to advanced clinical IT systems is like unlocking a door to seamlessly share data with the NHSBSA's MYS portal and GP records.

This is a significant move to support for the ongoing growth and improvement of community pharmacy services.

There will be fixed £1,000 monthly payments subject to £15 per consultation to support ongoing capacity to deliver Pharmacy First.

The new tripartite implementation group (CPE, DHSC, NHSE) to scrutinise the uptake and activity volumes of Pharmacy First and to set caps for the second half of 2024-25.

CPE successfully negotiated eligibility for the £1,000 Pharmacy First monthly payment to the provision of the Hypertension Case-Finding and Pharmacy Contraception Services given the capacity issues in the sector.

Janet Morrison, Chief Executive of Community Pharmacy England, said: “Our focus will now turn to getting the money flowing to pharmacies and to preparing our long-term strategy to improve the sector’s future.

"Pharmacy First will help with this strategy, laying the foundations for future clinical services and establishing the sector as an increasingly vital part of primary care, offering an open door for the public and patients, relieving pressure and releasing capacity in other frontline NHS services," she said.

Morrison further added: "This is the future that the sector told Nuffield Trust and The King’s Fund that it wanted, and this was backed by our own summer polling in which 86 per cent of respondents said they were positive about delivering a  Pharmacy First service. We all now need to work together to make it a success, delivering real value to patients and the public using all our skills and capabilities."

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less